Reader-supported. We may earn a commission when you use our partner links. How we’re funded
Our take
The $179 month-to-month option is the clearest comparison point. Resolve the longer-plan charge and policy scope before choosing a discounted tier.
What stands out
- Month-to-month price published
- Two administration formats listed
- Monthly check-ins and messaging described
What to weigh
- Longer-plan billing language conflicts
- Optional genetics does not establish treatment benefit
- Confirm which general terms apply to sermorelin
Use the month-to-month price as the starting point
PlexusDx lists $179 for a month-to-month sermorelin plan. Its discounted tiers show $149 per month for three months and $129 per month for six months. The product page describes one monthly charge, yet the general terms state that longer plans are prepaid in full. Those statements should be reconciled before choosing a discount.
Under the terms’ prepaid structure, the listed equivalents would calculate to $447 and $774 upfront respectively. These are arithmetic totals, not a verified checkout quote. The terms also specifically discuss weight-loss medications, leaving their scope for sermorelin worth confirming. Get the actual amount due, term length and next renewal in one written response rather than assuming the headline is the charge.
Two routes require a clinical discussion
The product page offers provider-selected subcutaneous injection or a sublingual formulation described using ODT and troche terminology. It says formulation does not change the price and includes provider care, medication and shipping. The oral option may interest readers who want to avoid injections, but convenience alone does not resolve suitability.
Ask which exact preparation the clinician recommends, why that route fits the intended use and what evidence supports its expected performance. Two formulations containing the same named ingredient are not automatically interchangeable. The pharmacy label should establish the actual route and directions; the storefront’s several oral labels should not become a reason for a patient to improvise how the medication is taken.
Genetics is an optional purchase
PlexusDx offers a $99 genetic test after the first month and promotes longevity-related genetic insights. It also describes monthly check-ins, unlimited messaging and provider-reviewed refills rather than automatic shipment. Those service features are more immediately relevant to the care comparison than the number of genetic insights advertised.
Before adding a test, ask what clinical decision its results would change and whether evidence supports that use for sermorelin. An association between a gene and longevity does not by itself demonstrate that testing predicts a useful treatment response. Keep the optional purchase separate from any laboratory testing the clinician considers necessary. That distinction makes both the budget and the clinical rationale easier to evaluate.
The cancellation language needs context
The general terms say canceling a prepaid plan stops renewal without creating a prorated refund of the current term. They describe preserving unused time during a pause and refunding unused, undispensed months when the clinician medically discontinues treatment. They also distinguish cancellation before pharmacy transmission from later change-of-mind requests.
Those protections and limits are more informative than a simple cancel-anytime banner, but their application to this product should be confirmed because of the terms’ medication scope. Ask what happens if a longer plan ends early for clinical reasons, how remaining value is calculated and whether a prescription already sent to a pharmacy can be stopped. Save the answer with the plan confirmation.
Our assessment of the offer
PlexusDx provides a clear monthly entry option and a useful choice of administration formats, subject to prescribing judgment. Its longer-term price presentation is less settled. Readers who value a simple budget may find the month-to-month quote easier to assess until the prepaid discrepancy is resolved.
Also confirm the consultation format for your state: the page promotes asynchronous access while acknowledging that some states require video. This October 2026 review is based on public pages rather than an enrollment or treatment experience. PlexusDx identifies the medication as compounded and not FDA-approved. Neither an optional genetic report nor a convenient subscription should substitute for a clinician’s explanation of whether this particular treatment is appropriate and what uncertainty remains.
Common questions
What is the month-to-month price?
The product page lists $179 per month. It also advertises $149 per month for three months and $129 per month for six months.
Are longer plans billed monthly?
Do not assume so. The product page describes a monthly charge, but the general terms say longer plans are prepaid in full. Confirm the actual charge and terms before enrollment.
Is the genetic test required?
No. The product page describes an optional $99 genetic test offered after the first month. It is not a required enrollment purchase.
Explore PlexusDx
See the current offer and decide whether you want to start a consultation.
Visit PlexusDxReader-supported. We may earn a commission when you use our partner links. How we’re funded
Sources & further reading
Provider prices and terms may change.